B13 MECHANISMS AND TREATMENT CONSIDERATIONS FOR SEVERE ASTHMA: Severe Asthma Patients On Oral Corticosteroid Therapy As A Distinct Phenotype: The European U-Biopred Cohort

摘要: Methods: Participants were recruited from adult pulmonary clinics across Europe and severe asthma diagnosed according to IMI-criteria (Bel et al. Thorax 2011). They had either uncontrolled asthma as defined by the GINA guidelines AND/OR two or more severe exacerbations in the past 12 months. Asthma diagnosis was confirmed by a history of typical symptoms and either reversibility in FEV1 of> 12% and 200ml after 400pg inhaled salbutamol OR airway hyperresponsiveness (PC20< 8 mg/ml) OR diurnal PEF variation OR a decrease in FEV1 of 12% after treatment tapering. Clinical and functional characteristics and inflammatory markers were collected. Independent T-test, Mann Whitney U test and Chi-square test were used.Results: In the 374 severe asthma participants, 167 (44%) were on oral prednisolone. The oral prednisolone group was older but had similar FEV1 (% predicted) and BMI. There was a …